Artemis Investment Management LLP Buys 56,830 Shares of Medpace Holdings, Inc. $MEDP

Artemis Investment Management LLP lifted its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 150.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 94,503 shares of the company’s stock after buying an additional 56,830 shares during the quarter. Artemis Investment Management LLP’s holdings in Medpace were worth $58,987,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of MEDP. Titleist Asset Management LLC raised its position in shares of Medpace by 13.7% in the 3rd quarter. Titleist Asset Management LLC now owns 473 shares of the company’s stock worth $295,000 after acquiring an additional 57 shares in the last quarter. Ausbil Investment Management Ltd boosted its position in shares of Medpace by 5.1% during the 3rd quarter. Ausbil Investment Management Ltd now owns 4,493 shares of the company’s stock valued at $2,804,000 after purchasing an additional 218 shares in the last quarter. Steph & Co. bought a new stake in shares of Medpace during the 3rd quarter valued at about $89,000. Congress Asset Management Co. grew its stake in Medpace by 3.4% during the third quarter. Congress Asset Management Co. now owns 60,479 shares of the company’s stock worth $37,750,000 after purchasing an additional 2,000 shares during the period. Finally, Cim Investment Management Inc. grew its stake in Medpace by 7.3% during the second quarter. Cim Investment Management Inc. now owns 1,137 shares of the company’s stock worth $602,000 after purchasing an additional 77 shares during the period. Institutional investors own 77.98% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the company. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $535.00 price target on shares of Medpace in a research note on Thursday, July 23rd. Weiss Ratings raised shares of Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, August 12th. Barclays lifted their price objective on shares of Medpace from $600.00 to $625.00 and gave the company an “equal weight” rating in a research note on Wednesday. Jefferies Financial Group reissued a “hold” rating on shares of Medpace in a research note on Monday, September 14th. Finally, BMO Capital Markets increased their target price on shares of Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a research note on Friday, July 24th. Three equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $607.73.

Insider Buying and Selling at Medpace

In other Medpace news, CEO August Troendle sold 49,018 shares of the business’s stock in a transaction dated Tuesday, September 22nd. The shares were sold at an average price of $628.11, for a total value of $30,788,695.98. Following the transaction, the chief executive officer directly owned 433,372 shares in the company, valued at $272,205,286.92. The trade was a 10.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last quarter, insiders have sold 336,140 shares of company stock valued at $208,008,328. 20.50% of the stock is currently owned by insiders.

Medpace Trading Down 1.6%

NASDAQ MEDP traded down $9.38 during mid-day trading on Thursday, hitting $594.87. The company’s stock had a trading volume of 77,989 shares, compared to its average volume of 328,197. The company’s 50 day simple moving average is $601.59 and its 200 day simple moving average is $524.87. Medpace Holdings, Inc. has a twelve month low of $373.00 and a twelve month high of $677.90. The firm has a market capitalization of $16.60 billion, a price-to-earnings ratio of 34.87, a PEG ratio of 2.69 and a beta of 1.18.

Medpace (NASDAQ:MEDP) last posted its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. The company had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The firm’s revenue was up 17.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, research analysts forecast that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

About Medpace

Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the product development process, from early planning and protocol design through clinical trials, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance and regulatory consulting.